APPROACHES FOR CANCER RESEARCH
Lee JC, Shirey RJ, Turner LD, Park H, Lairson LL, Janda KD. Discovery of PLD4 modulators by high-throughput screening and kinetic analysis. Results Chem. 2024; DOI: 10.1016/j.rechem.2024.101349. PMID: 38560090.
Karadkhelkar NM, Lin M, Eubanks LM, Janda KD. Demystifying the Druggability of the MYC Family of Oncogenes. J Am Chem Soc. 2023;145(6):3259-69. PMID: 36734615.
Shirey RJ, Turner LD, Lairson LL, Janda KD. Modulators of immunoregulatory exonucleases PLD3 and PLD4 identified by high-throughput screen. Bioorg Med Chem Lett. 2021;49:128293. PMID: 34332037.
Shirey RJ, Hart JR, Sridharan B, Novick SJ, Turner LD, Zhou B, Nielsen AL, Eubanks LM, Ueno L, Hixon MS, Lairson LL, Spicer TP, Scampavia LD, Griffin PR, Vogt PK, Janda KD. Synthetic fluorescent MYC probe: Inhibitor binding site elucidation and development of a high-throughput screening assay. Bioorg Med Chem. 2021;42:116246. PMID: 34130216.
Wang J, Merino DM, Light N, Murphy BL, Wang YD, Guo X, Hodges AP, Chau LQ, Liu KW, Dhall G, Asgharzadeh S, Kiehna EN, Shirey RJ, Janda KD, Taylor MD, Malkin D, Ellison DW, VandenBerg SR, Eberhart CG, Sears RC, Roussel MF, Gilbertson RJ, Wechsler-Reya RJ. Myc and loss of p53 cooperate to drive formation of choroid plexus carcinoma. Cancer Res. 2019;79(9):2208-19. PMID: 30885981.
Jacob NT, Miranda PO, Shirey RJ, Gautam R, Zhou B, de Orbe Izquierdo ME, Hixon MS, Hart JR, Ueno L, Vogt PK, Janda KD. Synthetic molecules for disruption of the MYC protein-protein interface. Bioorg Med Chem. 2018;26(14):4234-9. PMID: 30037753.
Cai X, Janda KD. A chemoenzymatic approach toward the preparation of site-specific antibody–drug conjugates. Tetrahedron Lett. 2015;56(23):3172-5.
Hart JR, Garner AL, Yu J, Ito Y, Sun M, Ueno L, Rhee JK, Baksh MM, Stefan E, Hartl M, Bister K, Vogt PK, Janda KD. Inhibitor of MYC identified in a Kröhnke pyridine library. Proc Natl Acad Sci U S A. 2014;111(34):12556-61. PMID: 25114221.
Jacob NT, Lockner JW, Kravchenko VV, Janda KD. Pharmacophore reassignment for induction of the immunosurveillance cytokine TRAIL. Angew Chem Int Ed Engl. 2014;53(26):6628-31. PMID: 24838721.
Raffeiner P, Röck R, Schraffl A, Hartl M, Hart JR, Janda KD, Vogt PK, Stefan E, Bister K. In vivo quantification and perturbation of Myc-Max interactions and the impact on oncogenic potential. Oncotarget. 2014;5(19):8869-78. PMID: 25326649.
Kravchenko VV, Gloeckner C, Stowe GN, Kang YJ, Tobias PS, Mathison JC, Ulevitch RJ, Kaufmann GF, Janda KD. The use of small molecule probes to study spatially separated stimulus-induced signaling pathways. Bioorg Med Chem Lett. 2012;22(5):2043-5. PMID: 22300658.
Garner AL, Janda KD. Protein-protein interactions and cancer: Targeting the central dogma. Curr Top Med Chem. 2011;11(3):258-80. PMID: 21320057.
Liu Y, Jiang P, Capkova K, Xue D, Ye L, Sinha SC, Mackman N, Janda KD, Liu C. Tissue factor-activated coagulation cascade in the tumor microenvironment is critical for tumor progression and an effective target for therapy. Cancer Res. 2011;71(20):6492-502. PMID: 21880589.
Uckun FM, Qazi S, Ozer Z, Garner AL, Pitt J, Ma H, Janda KD. Inducing apoptosis in chemotherapy-resistant B-lineage acute lymphoblastic leukaemia cells by targeting HSPA5, a master regulator of the anti-apoptotic unfolded protein response signalling network. Br J Haematol. 2011;153(6):741-52. PMID: 21517817.
Fukuchi K, Steiniger SC, Deryugina E, Liu Y, Lowery CA, Gloeckner C, Zhou B, Kaufmann GF, Quigley JP, Janda KD. Inhibition of tumor metastasis: Functional immune modulation of the CUB domain containing protein 1. Mol Pharm. 2010;7(1):245-53. PMID: 19916495.
Staflin K, Krueger JS, Hachmann J, Forsyth JS, Lorger M, Steiniger SC, Mee J, Pop C, Salvesen GS, Janda KD, Felding-Habermann B. Targeting activated integrin αvβ3 with patient-derived antibodies impacts late-stage multiorgan metastasis. Clin Exp Metastasis. 2010;27(4):217-31. PMID: 20225083.
Pires-Alves M, Ho M, Aberle KK, Janda KD, Wilson BA. Tandem fluorescent proteins as enhanced FRET-based substrates for botulinum neurotoxin activity. Toxicon. 2009;53(4):392-9. PMID: 19168088.
Steiniger S, Janda KD. The good, the bad, and the very bad: A new platform strategy to identify drug targets in cancer stem cells. BIOforum Europe. 2009;6:25.
Steiniger SC, Coppinger JA, Kruger JA, Yates J, 3rd, Janda KD. Quantitative mass spectrometry identifies drug targets in cancer stem cell-containing side population. Stem Cells. 2008;26(12):3037-46. PMID: 18802034.
Yoneda Y, Steiniger SC, Capkova K, Mee JM, Liu Y, Kaufmann GF, Janda KD. A cell-penetrating peptidic GRP78 ligand for tumor cell-specific prodrug therapy. Bioorg Med Chem Lett. 2008;18(5):1632-6. PMID: 18243696.
Zhou B, Carney C, Janda KD. Selection and characterization of human antibodies neutralizing Bacillus anthracis toxin. Bioorg Med Chem. 2008;16(4):1903-13. PMID: 18023190.
Liu Y, Steiniger SC, Kim Y, Kaufmann GF, Felding-Habermann B, Janda KD. Mechanistic studies of a peptidic GRP78 ligand for cancer cell-specific drug delivery. Mol Pharm. 2007;4(3):435-47. PMID: 17373820.
Kim Y, Lillo AM, Steiniger SC, Liu Y, Ballatore C, Anichini A, Mortarini R, Kaufmann GF, Zhou B, Felding-Habermann B, Janda KD. Targeting heat shock proteins on cancer cells: Selection, characterization, and cell-penetrating properties of a peptidic GRP78 ligand. Biochemistry. 2006;45(31):9434-44. PMID: 16878978.
Wu W, Luo Y, Sun C, Liu Y, Kuo P, Varga J, Xiang R, Reisfeld R, Janda KD, Edgington TS, Liu C. Targeting cell-impermeable prodrug activation to tumor microenvironment eradicates multiple drug-resistant neoplasms. Cancer Res. 2006;66(2):970-80. PMID: 16424032.
Felding-Habermann B, Lerner RA, Lillo A, Zhuang S, Weber MR, Arrues S, Gao C, Mao S, Saven A, Janda KD. Combinatorial antibody libraries from cancer patients yield ligand-mimetic Arg-Gly-Asp-containing immunoglobulins that inhibit breast cancer metastasis. Proc Natl Acad Sci U S A. 2004;101(49):17210-5. PMID: 15563590.
Lillo AM, Sun C, Gao C, Ditzel H, Parrish J, Gauss CM, Moss J, Felding-Habermann B, Wirsching P, Boger DL, Janda KD. A human single-chain antibody specific for integrin alpha3beta1 capable of cell internalization and delivery of antitumor agents. Chem Biol. 2004;11(7):897-906. PMID: 15271348.
Gao C, Mao S, Ronca F, Zhuang S, Quaranta V, Wirsching P, Janda KD. De novo identification of tumor-specific internalizing human antibody-receptor pairs by phage-display methods. J Immunol Methods. 2003;274(1-2):185-97. PMID: 12609544.
Liu C, Sun C, Huang H, Janda K, Edgington T. Overexpression of legumain in tumors is significant for invasion/metastasis and a candidate enzymatic target for prodrug therapy. Cancer Res. 2003;63(11):2957-64. PMID: 12782603.
Zhu X, Heine A, Monnat F, Houk KN, Janda KD, Wilson IA. Structural basis for antibody catalysis of a cationic cyclization reaction. J Mol Biol. 2003;329(1):69-83. PMID: 12742019.
Kozlov IA, Mao S, Xu Y, Huang X, Lee L, Sears PS, Gao C, Coyle AR, Janda KD, Wong CH. Synthesis of solid-supported mirror-image sugars: A novel method for selecting receptors for cellular-surface carbohydrates. ChemBioChem. 2001;2(10):741-6. PMID: 11948856.
Mao S, Gao C, Lo CH, Wirsching P, Wong CH, Janda KD. Phage-display library selection of high-affinity human single-chain antibodies to tumor-associated carbohydrate antigens sialyl Lewisx and Lewisx. Proc Natl Acad Sci U S A. 1999;96(12):6953-8. PMID: 10359820.
PUBLICATIONS
PUBLICATIONS BY TOPIC: